Annotation Detail
Information
- Associated Genes
- MET
- Associated Variants
-
MET AMPLIFICATION
(
ENST00000318493.11 )
MET AMPLIFICATION ( ENST00000318493.11 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1979
- Gene URL
- https://civic.genome.wustl.edu/links/genes/52
- Variant URL
- https://civic.genome.wustl.edu/links/variants/270
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Cetuximab,Crizotinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23729478
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cetuximab | Sensitivity | true |
| Crizotinib | Sensitivity | true |